SynthesisBreast cancer research and treatment2022
Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis.
Synthesis in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- HER2-low metastatic breast cancers: clinic-pathological characteristics, metastatic sites, and survival impact on biomarker discordance.Virchows Archiv : an international journal of pathology · 2026Article
- Prognostic impact of progesterone receptor status in patients with breast cancer and isolated locoregional recurrence.Breast cancer (Tokyo, Japan) · 2026Article
- The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer.Journal of cancer research and clinical oncology · 2026Article
- Genomic and transcriptomic evaluation of primary and recurrent luminal B-like breast cancer.ESMO open · 2026Article
- The Current Landscape of Metastatic Breast Cancer: A Pathology Guide on Emerging Biomarkers.Cancers · 2026Review
- Residual Primary Breast Cancer After Chemotherapy: Assessment of Recurrence and Survival.Cureus · 2026Article
- A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing.Genome medicine · 2026Article
- Receptor Discordance and Molecular Subtype Changes in Visceral Metastases of Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Development and multicenter external validation of an intratumoral and peritumoral ultrasound-based radiomics model for preoperative prediction of HER2 status in IHC 2 + breast cancer.European journal of medical research · 2025Article
- Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease.Breast cancer research and treatment · 2024Review
- Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival.Breast cancer research and treatment · 2024Article
- Estrogen-Receptor Loss andCancers · 2024Article
- Biomarker conversion from primary breast cancer to synchronous axillary lymph node metastasis and neoadjuvant therapy response: a single-center analysis.Journal of cancer research and clinical oncology · 2024Article
- Receptor discordance after nipple-sparing mastectomy.Surgery in practice and science · 2024Article
- Study of Biomarker Discordance between Primary and Recurrent Sites and its Clinical Implications in Metastatic Breast Cancer : A Single Institutional Study from India.South Asian journal of cancer · 2024Article
- Article
- A prediction model for distant metastasis after isolated locoregional recurrence of breast cancer.Breast cancer research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis meta-analysis aimed to investigate whether receptor (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]) discordances between primary and recurrent breast cancers affect patients' survival.
methodsSearch terms contained ER, PR, and HER2 status details in both primary and recurrent tumors (local recurrence or distant metastasis) in addition to survival outcome data (overall survival [OS] or post-recurrence survival [PRS]).
resultsLoss of ER or PR in recurrent tumors was significantly associated with shorter OS as compared with receptor-positive concordance (hazard ratio [HR], 1.67; 95% confidence interval [% CI] 1.37-2.04; p < 0.00001 and HR, 1.45; 95% CI 1.21-1.75; p < 0.0001, respectively). Similar trends were observed in groups with only distant metastasis. Gain of ER was a significant predictor of longer PRS as compared with receptor-negative concordance (HR, 0.76; 95% CI 0.59-0.97; p = 0.03). Gain of PR was not a significant predictor of longer survival compared with receptor-negative concordance, but it could be related to better OS at distant metastasis. Both HER2 of loss and gain could be related to poor outcomes.
conclusionThis meta-analysis showed that receptor conversion in recurrent tumors may affect patient survival as compared with receptor concordance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.